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Abstract  
We have evaluated prospectively the prevalence of other autoimmune disorders in 
outpatient clinic in 3069 consecutive patients with diagnosed chronic autoimmune 
thyroiditis (AT), with respect to two age- and sex-matched control groups: a) a control 
group of 1023 subjects, extracted from a random sample of the general population 
without thyroid disorders; b) 1023 patients with non-toxic multinodular goiter 
extracted from the same random sample of the general population, with similar odine 
intake. The results of our study demonstrate a significant increase of the prevalence of 
autoimmune disorders in AT patients (with respect to both controls), for the following 
diseases: chronic autoimmune gastritis (CAG), vitiligo (Vit), rheumatoid arthritis, 
polymialgia rheumatica (Polym), celiac disease, diabetes, sjogren disease, multiple 
sclerosis, systemic lupus erythematosus, sarcoidosis, alopecia, psoriathic arthritis, 
systemic sclerosis, HCV-related cryoglobulinemia. While the statistical analysis 
reached near the significance for Addison’s disease and ulcerative colitis. 
Interestingly, the association of three autoimmune disorders was observed almost 
exclusively in AT patients, and the most frequent associations were AT+CAG+Vit 
and AT+CAG+Polym.  
We suggest that patients with AT who remain unwell, or who develop new not 
specific symptoms (despite adequate treatment) should be screened for other 
autoimmune disorders, avoiding the delay in the diagnosis of these disorders. 
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Take-home messages: 
• Associations exist between autoimmune thyroid diseases (AITD) and other organ 
specific, or systemic autoimmune disorders. 
• However, the small sample sizes and the use of control populations not matched 
for age, or gender, or geographic location, might have hampered the results of 
several studies. 
• Our study demonstrate a significant increase of the prevalence of autoimmune 
disorders in AT patients (with respect to two age and gender matched controls, of 
same geographic area), for the following diseases: chronic autoimmune gastritis, 
vitiligo, rheumatoid arthritis , polymyalgia rheumatica, celiac disease, diabetes, 
sjogren disease, multiple sclerosis, systemic lupus erythematosus, sarcoidosis, 
alopecia, psoriathic arthritis, systemic sclerosis, HCV-related cryoglobulinemia. 
• The statistical analysis reached near the significance for Addison’s disease and 
ulcerative colitis. 
• The association of three autoimmune disorders was observed almost exclusively in 
AT patients, and the most frequent associations were autoimmune thyroiditis+ 
chronic autoimmune gastritis+vitiligo and autoimmune thyroiditis+ chronic 
autoimmune gastritis+ polymyalgia rheumatica.  
• We suggest that patients with AT, being still unwell, or developing new not 
specific symptoms (though adequate treatment) should be screened for other 
autoimmune disorders, avoiding the delay in the diagnosis of these ones. 
1. Introduction 
Associations exist between autoimmune thyroid diseases (AITD) and other organ 
specific, or systemic autoimmune disorders [1-3]. 
Thyroid function abnormalities and thyroid autoantibodies have been frequently 
described in patients with systemic rheumatological autoimmune diseases, as 
Sjögren’s syndrome, rheumatoid arthritis, systemic lupus erythematosus and systemic 
sclerosis [1, 4, 5].  
Recent studies showed a greater prevalence of the association between AITD and 
rheumatic diseases [as Sjögren’s syndrome, rheumatoid arthritis, systemic lupus 
erythematosus, systemic sclerosis, mixed cryoglobulinemia, sarcoidosis, or psoriathic 
arthritis], highlighting the possibility of common pathogenic mechanisms among them 
[4, 6-8].  
More recently, a first study has evaluated longitudinally the incidence of new cases of 
thyroid autoimmunity and dysfunction in female patients with systemic sclerosis 
showing a high incidence of new cases of hypothyroidism, thyroid dysfunction, anti-
thyroperoxidase (AbTPO) positivity. The appearance of hypothyroidism was related 
to a borderline high initial thyroid-stimulating hormone level, AbTPO positivity, and 
a hypoechoic and small thyroid. This study suggests that these patients should have 
periodic thyroid function follow-up [9].  
Many studies underline the importance of a common genetic susceptibility (HLA, etc) 
in patients with AITD and systemic autoimmunity [1-3]. Even environmental factors 
could be implicated in the association of autoimmune disorders [1]. 
Serum and/or tissue CXCL10 expression is increased in organ specific autoimmune 
diseases, as autoimmune thyroiditis (AT), Graves’ disease, type 1 diabetes, and/or 
systemic rheumatological disorders (like rheumatoid arthritis, systemic lupus 
erythematosus, systemic sclerosis, mixed cryoglobulinemia), underlining the 
importance of a common immunopathogenesis of these disorders, characterized by a 
Th1 prevalent autoimmune response [1]. These studies suggest that patients with 
systemic autoimmune disorders should have periodic thyroid follow-up. 
Here we report our experience in a prospective study that evaluated the prevalence of 
other autoimmune disorders in subjects with AT. 
 
 
2. Methods 
 
2.1. Patients  
From 1993 to 2008 we have evaluated prospectively the prevalence of other 
autoimmune disorders in outpatient clinic in 3069 consecutive Caucasian patients 
with diagnosed chronic AT (Table 1). The patients were referred to us by general 
practitioners or other hospitals because of the presence of circulating thyroid 
autoantibodies or hypothyroidism, or clinical suspicion of a thyroid disorder. The 
diagnosis of AT [10,11] was established from the clinical presentation (presence of a 
firm goiter, varying in size from small to very large, with a lobulated surface), thyroid 
hormones and thyroid autoantibodies measurements, and/or thyroid ultrasonography 
(decreased, dyshomogeneous echogenicity). The majority of these patients had a 
normal thyroid volume, some showed goiter (11%) or atrophic thyroiditis (9%). A 
minority of patients (5%) were submitted to fine-needle aspiration to exclude the 
presence of thyroid cancer or lymphoma; in these cases, cytology confirmed the 
presence of a lymphocytic infiltration.  
2.2. Controls 
Matched control groups were used (Table 1).  
The prevalence of autoimmune disorders was evaluated in two age- and sex-matched 
control groups (three patients/one control). 
The first control group (n=1023) consisted in subjects extracted from a random 
sample of the general population from the same geographic area [12] in whom a 
complete thyroid work-up [history, physical examination, thyroid-stimulating 
hormone (TSH), free triiodothyronine (FT3), free thyroxine (FT4), anti-thyroglobulin 
(AbTg) and AbTPO antibodies measurements, and ultrasonography] was available, 
and excluded the presence of thyroid disorders.  
A second control group comprised 1023 patients with non-toxic multinodular goiter 
(MNG) extracted from the same random sample of the general population. The 
majority of these patients had a normal thyroid volume, some showed goiter (28%).  
In all patients and controls, a blood sample was collected in the morning, after 
overnight fasting, and serum was kept frozen until thyroid hormones, and thyroid 
autoantibodies measurements. 
All study subjects gave their informed consent to the study, which was approved by 
the local Ethical Committee.  
All patients and controls were submitted to thyroid ultrasonography and fine-needle 
aspiration, if necessary; cytology confirmed the absence of a malignancy. 
Thyroid blood flow by color-flow doppler was also studied in all patients [13], and 
controls.  
2.3. Laboratory evaluation  
Thyroid function and thyroid autoantibodies were measured as previously described 
[10]. Circulating FT3 and FT4 were measured by commercial RIA kits (AMERLEX-
MAB FT3/FT4 Kit; Amersham, UK). Serum TSH (DiaSorin, USA), AbTPO and 
AbTg (ICN Pharmaceuticals, USA) were evaluated by IRMA methods. For AbTg, 
AbTPO, positivity was set at > 50, and >10 IU/mL, respectively. 
2.4. Evaluation of other autoimmune diseases 
Patients were interviewed by a specialist physician at enrollment into the study. A 
structured questionnaire was completed seeking other common autoimmune diseases 
in the patients and controls. Diagnoses of other autoimmune disorders also were based 
on patient recall, with verification in the index case through cross-checking with 
current records and medications by the recruiting physicians. Furthermore any 
diagnosis of autoimmune disease was verified by a specialist (rheumatology, 
dermatology, gastroenterology or internal medicine) and confirmed or not on the base 
of the criteria proposed by the scientific societies for each specific disease [14]. 
Only if there was a confirming evidence of coexisting autoimmune diseases the 
patient was considered positive for the specific disorder.  
2.5. Data analysis  
Values are given as mean ± SD for normally distributed variables. Mean group values 
were compared by using one-way analysis of variance (ANOVA) for normally 
distributed variables, otherwise by the Mann-Whitney U test. Proportions were 
compared by the χ2 test. Post-hoc comparisons on normally distributed variables were 
carried out using the Bonferroni-Dunn test.  
 
3. Results  
The thyroid evaluation of AT, and MNG patients vs. controls is reported in Table 1. 
About 26% of AT patients were hypothyroid, while no case of hypothyroidism was 
present in MNG patients and controls. 
A high prevalence of autoimmune diseases was observed in AT patients (Table 2) in 
comparison with controls or MNG patients. The 10 most frequently observed 
autoimmune diseases in AT patients were: chronic autoimmune gastritis (2.8%), 
vitiligo  (2.7%), rheumatoid arthritis  (2.4%), polymyalgia rheumatica (1.4%), celiac 
disease (1.3%), diabetes (type 1) (1%), sjogren disease (0.9%), multiple sclerosis 
(0.9%), systemic lupus erythematosus (0.8%), sarcoidosis (0.6%).  
A significant increase of the prevalence of autoimmune disorders in AT patients was 
observed, with respect to both control groups, for the following diseases: chronic 
autoimmune gastritis, vitiligo , rheumatoid arthritis  , polymyalgia rheumatica, celiac 
disease, diabetes (type 1), sjogren disease, multiple sclerosis, systemic lupus 
erythematosus, sarcoidosis, alopecia, psoriathic arthritis, systemic sclerosis, hepatitis 
C virus (HCV)-related cryoglobulinemia. The statistical analysis reached near the 
significance for Addison’s disease and ulcerative colitis, while no significant trend 
was observed for the other disorders.  
The association of three autoimmune disorders was observed in 36 patients with AT, 
only in 1 subject in controls, and no MNG patient (Table 3). The most frequent 
associations were AT+chronic autoimmune gastritis (CAG)+vitiligo (Vit) and 
AT+CAG+ polymyalgia rheumatica (Polym). 
 
4. Discussion 
It is well known that AT can be associated with increased prevalences of type 1 
diabetes [15], vitiligo [16], Addison’s disease [17], and multiple sclerosis [18]. 
However, the small sample sizes and the use of control populations not matched for 
age, or gender, or geographic location, might have hampered the results of several 
studies [19]. 
More recently a cross-sectional multicenter study of 3286 UK Caucasian subjects 
(2791 with Graves’ disease; 495 with Hashimoto’s thyroiditis) evaluated the 
coexistence of autoimmune disorders by a structured questionnaire. The frequency of 
another autoimmune disorder was 14.3% in AT patients. The most prevalent 
autoimmune disorders in AT patients were rheumatoid arthritis, pernicious anemia, 
systemic lupus erythematosus, Addison’s disease, celiac disease, and vitiligo [20].  
With respect to the above mentioned paper, our study has some important strength 
points: 1) it is a prospective study; 2) the relative risk for each of the different 
autoimmune diseases was calculated by dividing the observed prevalence by the best 
estimate of UK population prevalence based on the current literature in the Boelaert 
study (that was lacking of an appropriate internal control group); 3) two control 
groups matched by age and gender (that are important risk factor for thyroid 
autoimmunity) are present in our study, ruling out the influence of these parameters 
on the final results; 4) a control group of subjects from the general population in 
whom a complete thyroid screening excluded the presence of thyroid autoimmune 
disorders permits to higlight the difference with AT patients; 5) a control group of 
patients with MNG without thyroid autoimmunity permits to exclude the possible 
influence of non autoimmune thyroid pathologies on the final results; 6) a higher 
number of AT patients (3069 vs. 495) were studied; 7) the presence of other 
autoimmune disorders was verified by a specialist (rheumatology, dermatology, 
gastrenterology or internal medicine) and confirmed or not on the base of the criteria 
proposed by the scientific societies for each specific disease (not on the base of a 
questionnaire); 8) a larger number of autoimmune diseases have been investigated. 
The results of our study demonstrate a significant increase of the prevalence of 
autoimmune disorders in AT patients (with respect to both controls), for the following 
diseases: chronic autoimmune gastritis, vitiligo, rheumatoid arthritis, polymyalgia 
rheumatica, celiac disease, diabetes, sjogren disease, multiple sclerosis, systemic 
lupus erythematosus, sarcoidosis, alopecia, psoriathic arthritis, systemic sclerosis, 
HCV-related cryoglobulinemia. While the statistical analysis reached near the 
significance for Addison’s disease and ulcerative colitis. On the whole however an 
increased prevalence of autoimmune diseases in AT patients have been shown. The 
statistical significance for some of the other autoimmune disorders is difficult to be 
reached, because of the low prevalence of these disorders (for example primary 
biliary cirrhosis, or dermatomyositis, etc); so larger samples of patients are needed to 
confirm or not these associations. 
Interestingly, the association of three autoimmune disorders was observed almost 
exclusively in AT patients, and the most frequent associations were AT+CAG+Vit 
and AT+CAG+Polym. 
The influence of genetics on the association of different autoimmune disorders has 
been shown, in fact:  a)  there  is significant clustering of autoimmune thyroid 
disease within families (40% to 50% of AT patients report another family member  
with AT) [21] ; b) a clear evidence arises from twin studies for Graves’ disease [22] 
and AT [23] with concordance rates of 30-40% in monozygotic twins and 0-7% in 
dizygotic twins. 
However the precise pathogenetic mechanisms are not known, and AT is believed to 
result from an interaction between the products of genes conferring susceptibility with 
various environmental triggers [24].  
Immunopathological studies have shown that in target organs of patients with chronic 
AT, or Graves' ophthalmopathy, or type 1 diabetes, at the onset of these diseases, a 
prevalent Th1 immune profile is present, as reported from animal models and in 
humans [25,26]. For example in the initial and active phase of mixed 
cryoglobulinemia, a predominant Th1 immune response is shown, that in the inactive 
phase switches to Th2 [27,28]. The predominance of a Th1 immune profile at the 
beginning of AT and other autoimmune disorders, and the effects of genetic and 
environmental conditions, could lead to the onset of autoimmune phenomena 
interesting various organs in the same subject [1,29,30]. 
In conclusion, we demonstrate a significant increased risk of other autoimmune 
diseases in patients with AT. We suggest that patients with AT, being still unwell, or 
developing new not specific symptoms (though adequate treatment) should be 
screened for other autoimmune disorders, avoiding the delay in the diagnosis of these 
ones. 
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 Table 1. Thyroid status of control subjects and patients with thyroditis. 
  
 
Controls AT MNG P 
 
N 1023 3069 1023  
     
Age (years) 53 ± 15 54 ± 16 54 ± 13 ns 
     
Gender (% M/F) 27/73 27/73 27/73 ns 
     
Thyroid volume 10 ± 3 9 ± 7 15 ± 9*° 0.007 
     
Hypoechoic (%) 0 71 0 0.0001 
     
Hypervascularity (%) 0 27 0 0.0001 
     
TSH (µΙU/mL) 1.5 ± 0.7 3.4 ± 4.7°§ 1.0 ± 0.6 0.0006 
     
AbTPO (IU/mL) 9 ± 6 367 ± 302°^ 8 ± 9 0.0001 
     
AbTg (IU/mL) 11 ± 10 189± 419°^ 17 ± 19 0.0001 
     
AbTPO positivity (%) 0 81 0 0.0001 
     
AbTg positivity (%) 0 63 0 0.0001 
     
Hypothyroidism      
Serum TSH > 3.5 µΙU/mL (%) 0 26 0 0.001 
          
Antithyroperoxidase antibody = AbTPO    
Antithyroglobulin antibody = AbTg     
Thyroid-stimulating hormone = TSH    
P < 0.005 MNG vs. Controls = *     
P < 0.005 MNG vs. AT = °     
P < 0.01 TH vs. Controls = § or MNG < 0.01^    
 
Table 2.  Distribution of autoimmune diseases in AT patients, MNG and controls. 
 Controls 
n = 1023 
AT 
n = 3069 
MNG 
n = 1023 
P 
χ2 
Diabetes (type 1)  2 31 0 0.0003 
Addison disease 0 7 0 0.0967 
Chronic autoimmune gastritis 6 87 9 < 0.0001 
Celiac disease 2 39 3 0.0005 
Crohn disease 1 12 1 0.1446 
Ulcerative colitis 1 17 2 0.0688 
Vitiligo   5 83 2 < 0.0001 
Alopecia 1 16 0 0.0148 
Psoriasis 2 12 3 0.6237 
Psoriatic arthritis 2 18 0 0.0180 
Myasthenia gravis 0 3 0 0.3677 
Polymyalgia rheumatica 3 44 5 0.0012 
Polymyositisy/dermatomyositis  0 5 0 0.1886 
Primary biliary cirrhosis 0 4 1 0.5131 
Chronic autoimmune hepatitis 0 3 0 0.3675 
Rheumatoid arthritis   7 74 5 < 0.0001 
Systemic sclerosis (scleroderma)  0 16 0 0.0047 
Sjogren disease 2 27 0 0.0001 
Systemic lupus erythematosus 1 25 0 0.0008 
Sarcoidosis 2 19 0 0.0133 
HCV-related cryoglobulinemia 0 17 0 0.0034 
Not–HCV-related cryoglobulinemia 0 2 0 0.5133 
Glomerulonephritis Primary  IgA 0 1 0 0.7165 
Multiple sclerosis  3 27 2 0.0179 
 Uveitis (iridocyclitis) 2 9 4 0.7158 
Wegener granulomatosis  0 1 0 0.7165 
Total 40 (3.9%) 599 (19.5%) 37 (3.6%) < 0.0001 
Table 3. Patients with 3 associated autoimmune disorders in AT, MNG and controls. 
 Controls 
n = 1023 
AT 
n = 3069 
MNG 
n = 1023 
P 
χ2 
AT+CAG+Vit 0 12 0 0.0181 
AT+CAG+Polym 0 5 0 ns 
AT+CAG+Alo 0 2 0 ns 
AT+CAG+T1D 0 2 0 ns 
AT+CAG+SLE 0 1 0 ns 
AT+CAG+Sarc 0 1 0 ns 
AT+CAG+SSc 0 1 0 ns 
AT+CAG+Sjog 0 1 0 ns 
AT+Vit+Sjog 0 1 0 ns 
AT+Vit+Polym 0 2 0 ns 
AT+T1D+CelDis 0 2 0 ns 
AT+RA+Vit 0 2 0 ns 
AT+Sarc+Vit 0 1 0 ns 
AT+Polym+UlcCol 0 1 0 ns 
AT+Crohn+Vit 0 1 0 ns 
AT+Sarc+Vit 0 1 0 ns 
CAG+Vit+RA 1 0 0 ns 
Total 1 36 0 < 0.0001 
Alopecia (Alo); autoimmune thyroiditis = AT; celiac disease (CelDis); chronic 
autoimmune gastritis (CAG); Crohn disease (Crohn); polymyalgia rheumatica 
(Polym); rheumatoid arthritis (RA); sarcoidosis (sarc); sjögren’s syndrome (Sjog); 
systemic lupus erythematosus (SLE); systemic sclerosis (SSc); type 1 diabetes (T1D); 
ulcerative colitis (UlcCol); vitiligo (Vit). 
 
 
